Evidence map›Paper›PMID 36620575›Full record

ArticleFrontiers in oncology2022

Case Report: Stage IIIc primary malignant mixed Müllerian tumor of the fallopian tube: A case of 5-year disease-free survival after cytoreductive surgery combined with peritoneal resection and adjuvant chemotherapy with paclitaxel plus carboplatin.

Xiaoli Xiao, Ruiqing Ma, Lianyao Shi, Cong Wang, Jie Chen, Yiyan Lu, Yufeng Wang, Xichao Zhai, Fengxian Fu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaoli XiaoDepartment of Gynecology, Aerospace Center Hospital, Beijing, China.
Ruiqing MaDepartment of Myxoma, Aerospace Center Hospital, Beijing, China.
Lianyao ShiDepartment of Gynecology, Aerospace Center Hospital, Beijing, China.
Cong WangDepartment of Gynecology, Aerospace Center Hospital, Beijing, China.
Jie ChenDepartment of Imaging, Aerospace Center Hospital, Beijing, China.
Yiyan LuDepartment of Pathology, Aerospace Center Hospital, Beijing, China.
Yufeng WangDepartment of Ultrasonography, Aerospace Center Hospital, Beijing, China.
Xichao ZhaiDepartment of Myxoma, Aerospace Center Hospital, Beijing, China.
Fengxian FuDepartment of Gynecology, Aerospace Center Hospital, Beijing, China.
Aerospace Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mixed Müllerian tumor (MMMT) of the fallopian tube is rare and has a poor prognosis. For the patient with fallopian tube MMMT, complete resection of the tumor invading the viscera and the peritoneum is a prerequisite for long-term survival. We report a case of stage IIIc MMMT of the fallopian tube treated by cytoreductive surgery (CRS), peritoneal resection, and adjuvant chemotherapy (paclitaxel plus carboplatin), with 5-year tumor-free survival. Postoperative chemotherapy combining platinum and paclitaxel is the most potent adjuvant therapy.

Indexed as

cytoreduction scorecytoreductive surgery (CRS)malignant mixed Müllerian tumor (MMMT)postoperative chemotherapy (POCT)tumor-free survival

Identifiers

PMID36620575
PMCPMC9815857
OpenAlexW4312187337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.